Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.
Montillo M, Tedeschi A, Miqueleiz S, Veronese S, Cairoli R, Intropido L, Ricci F, Colosimo A, Scarpati B, Montagna M, Nichelatti M, Regazzi M, Morra E. Montillo M, et al. J Clin Oncol. 2006 May 20;24(15):2337-42. doi: 10.1200/JCO.2005.04.6037. Epub 2006 Apr 17. J Clin Oncol. 2006. PMID: 16618945 Clinical Trial.
Role of fludarabine in hematological malignancies.
Montillo M, Ricci F, Tedeschi A. Montillo M, et al. Expert Rev Anticancer Ther. 2006 Sep;6(9):1141-61. doi: 10.1586/14737140.6.9.1141. Expert Rev Anticancer Ther. 2006. PMID: 17020450 Review.
Relationship between pharmacokinetic profile of subcutaneously administered alemtuzumab and clinical response in patients with chronic lymphocytic leukemia.
Montagna M, Montillo M, Avanzini MA, Tinelli C, Tedeschi A, Visai L, Ricci F, Vismara E, Morra E, Regazzi M. Montagna M, et al. Among authors: montillo m. Haematologica. 2011 Jun;96(6):932-6. doi: 10.3324/haematol.2010.033159. Epub 2011 Feb 17. Haematologica. 2011. PMID: 21330330 Free PMC article. Clinical Trial.
An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia.
Montillo M, Tedeschi A, Petrizzi VB, Ricci F, Crugnola M, Spriano M, Spedini P, Ilariucci F, Uziel L, Attolico I, Vismara E, De Blasio A, Zaccaria A, Morra E. Montillo M, et al. Blood. 2011 Oct 13;118(15):4079-85. doi: 10.1182/blood-2011-05-351833. Epub 2011 Jul 19. Blood. 2011. PMID: 21772050 Free article. Clinical Trial.
175 results